Konruns(SH:603590) Xin Lang Cai Jing·2025-09-25 05:23Group 1 - The core point of the news is that Kangchen Pharmaceutical experienced a 5.01% drop in stock price, closing at 52.15 yuan per share, with a trading volume of 137 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 8.31 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, focuses on innovative drug research and development, with its main business revenue composition being 70.77% from Suling, 29.15% from Salmon Calcitonin (Mikazis), and 0.09% from other sources [1] Group 2 - According to data, one fund under Xinda Aoya holds a significant position in Kangchen Pharmaceutical, with the Xinao Health China Mixed A Fund (003291) holding 730,600 shares, accounting for 3.38% of the fund's net value, ranking as the tenth largest holding [2] - The Xinao Health China Mixed A Fund has a current scale of 534 million yuan, with a year-to-date return of 34.35%, ranking 2667 out of 8173 in its category, and a one-year return of 43.89%, ranking 3547 out of 8003 [2] Group 3 - The fund managers of Xinao Health China Mixed A Fund are Li Junzhou and Yang Ke, with Li having a tenure of 112 days and a total fund size of 680 million yuan, achieving a best return of 20.57% and a worst return of 20.3% during his tenure [3] - Yang Ke has a tenure of 5 years and 137 days, managing a total fund size of 1.445 billion yuan, with a best return of 55.92% and a worst return of -13.42% during his tenure [3]